Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06143956 · ClinicalTrials.gov registry record · Phase 2
A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
A Phase 2 study of Obesity and Overweight, sponsored by Eli Lilly and Company.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 1,217
- Enrollment target
- 20
- Study locations
NCT06143956: Recruiting Phase 2 study of Obesity and Overweight, sponsored by Eli Lilly and Company.
NCT06143956 is a Phase 2 study of Obesity and Overweight that is actively recruiting participants, run by Eli Lilly and Company. The registered enrollment target is 1,217 participants, above the 818-participant average among 1,053 other Obesity trials with a reported enrollment target (49% higher). The trial reports 20 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06143956, a Phase 2 study of Obesity and Overweight, is actively recruiting participants, sponsored by Eli Lilly and Company.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 1,217 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this Phase-2 chronic weight management master protocol (CWMM) is to create a framework to evaluate the safety and efficacy of various investigational interventions for chronic weight management with intervention-specific appendices (ISAs). The CWMM establishes entry criteria for newly enrolled participants across the master and the ISAs. The ISAs may start independently of other ISAs as interventions become available for clinical testing. The results for the CWMM screening record will be reported when all the ISA's complete.
Primary Outcome
Each ISA will detail the intervention specific analysis.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Tirzepatide
- DRUG LY3305677
- DRUG LY3841136
- DRUG LY3549492
Study Locations (20)
Florida
- Northeast Research Institute (NERI) - Fleming Island
- Indago Research & Health Center, Inc - Hialeah
- New Horizon Research Center - Miami
- Suncoast Clinical Research, Inc. - New Port Richey
- Charter Research - Winter Park - Orlando
- Charter Research - Lady Lake - The Villages
Arizona
- The Institute for Liver Health II dba Arizona Clinical Trials - Mesa - Chandler
- HOPE Research Institute - Phoenix
- Headlands Research - Scottsdale - Scottsdale
- The Institute for Liver Health II dba Arizona Liver Health-Tucson - Tucson
California
- NorCal Medical Research, Inc - Greenbrae
- Velocity Clinical Research, Huntington Park - Huntington Park
- Peninsula Research Associates - Rolling Hills Estates
- Diablo Clinical Research, Inc. - Walnut Creek
Illinois
- Great Lakes Clinical Trials - Ravenswood - Chicago
- Great Lakes Clinical Trials - Ravenswood - Chicago
- NorthShore University Health System - Skokie
Connecticut
- Stamford Therapeutics Consortium - Stamford
Hawaii
- Pacific Diabetes & Endocrine Center - Honolulu
Idaho
- Medical Research Partners - Ammon
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,217 participants |
| Start Date | 2023-11-17 |
| Est. Completion | 2026-09 |
| Phase | Phase 2 |
What NCT06143956 shows while recruiting
NCT06143956 is an interventional study that assigns participants to a tested intervention. Its 1,217 participants enrollment target places it among the larger protocols in the corpus, above the 818-participant average among 1,053 other Obesity trials with a reported enrollment target (49% higher).
The record links to 2 conditions, with Obesity appearing as the primary indexed condition, and to 5 interventions - of which Placebo is the first listed.
NCT06143956 names 20 study sites across 7 states, led by Florida, Arizona, California.
Frequently Asked Questions
What is clinical trial NCT06143956 about?
NCT06143956 is a clinical study titled "A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight". The purpose of this Phase-2 chronic weight management master protocol (CWMM) is to create a framework to evaluate the safety and efficacy of various investigational interventions for chronic weight management with intervention-specific appendices (ISAs). The CWMM establishes entry criteria for newly...
What is the current status of trial NCT06143956?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 1,217 participants. The study started on 2023-11-17. Estimated completion is 2026-09.
What conditions does trial NCT06143956 study?
This clinical trial studies the following conditions: Obesity, Overweight.
What interventions are being tested in trial NCT06143956?
The interventions under investigation include: Placebo (DRUG), Tirzepatide (DRUG), LY3305677 (DRUG), LY3841136 (DRUG), LY3549492 (DRUG).
Who is sponsoring clinical trial NCT06143956?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06143956 being conducted?
This trial has 20 study locations across Arizona, California, Connecticut, Florida, Hawaii. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06143956's enrollment target sits among peer trials
1,217 64th of 1053 higher than 990 of 1,053 other Obesity trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Obesity trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
TIRzepatide for the Treatment of Obesity in Patients With Atrial Fibrillation
RECRUITING · Phase 2
-
Tirzepatide: Reversal of Lipotoxicity and Adipose Tissue Dysfunction in Humans With Overweight/Obesity
RECRUITING · Phase 2
-
Convergent Mechanisms Underlying Reprometabolic Syndrome in Women
RECRUITING · Phase 2
-
Arterial Destiffening Effects of SGLT2 Inhibition in Veterans With Obesity
RECRUITING · Phase 2
-
Pharmacological and Behavioral Treatment After Bariatric Surgery
RECRUITING · Phase 2
-
A Novel Obesity Prevention Program for High-Risk Infants in Primary Care
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05827016 · 1,216 participants · Phase 3
A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma
- NCT06921785 · 1,220 participants · Phase 3
Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
- NCT04267848 · 1,210 participants · Phase 3
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
- NCT05946213 · 1,209 participants · Phase 3
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI